Eli Lilly Acquires AtaiBeckley for $2.8 Billion to Expand Neuroscience Portfolio
On July 16, Eli Lilly announced the acquisition of clinical-stage biotech company AtaiBeckley (NASDAQ: ATAI) for approximately $2.8 billion in cash. The deal aims to strengthen Eli Lilly's neuroscience portfolio by adding promising candidates like BPL-003, an investigational drug for treatment-resistant depression that has shown strong phase 2 results. This acquisition is part of a broader strategy as the company continues expanding its pipeline through multiple acquisitions across various therapeutic areas such as pain management and oncology. In June alone, Eli Lilly acquired Centessa Pharmaceuticals (NASDAQ: CNTA) for $6.3 billion to bolster its narcolepsy treatment portfolio. The move into neuroscience complements Eli Lilly's existing Alzheimer’s drug Kisunla, which is expected to reach peak sales of over $1 billion. While the company remains a leader in GLP-1 drugs and weight management therapies like Zepbound, it faces increasing competition that could pressure pricing power. By diversifying its pipeline across multiple therapeutic areas, Eli Lilly aims to maintain long-term growth despite potential challenges.
Topics: Biotech acquisition Depression treatment Neuroscience Pharmaceuticals